Immunodiagnostic Systems Hldgs PLC Launch of IDS-iSYS ACTH assay (9108V)
February 02 2017 - 10:14AM
UK Regulatory
TIDMIDH
RNS Number : 9108V
Immunodiagnostic Systems Hldgs PLC
02 February 2017
Immunodiagnostic Systems Holdings plc.
2 February 2016
Launch of IDS-iSYS ACTH assay - new assay in the IDS
hypertension portfolio
Immunodiagnostic Systems Holdings plc (IDS), a specialty
solution provider to the clinical laboratory diagnostic market,
today launched the IDS-iSYS ACTH assay in the European market - a
fully automated assay for use with the IDS-iSYS Automated
System.
The IDS-iSYS ACTH assay will become a key assay within the
existing IDS portfolio for endocrine hypertension testing.
The IDS-iSYS ACTH assay measures a patient's levels of
adrenocorticotropic hormone to allow the assessment of pituitary
and adrenal gland function. Together with other clinical and
laboratory data it allows the differential diagnosis of hyper- and
hypo-cortisolism disorders such as Cushing's syndrome and Addison's
disease, as well as the evaluation of other causes of endocrine
hypertension.
The Global market size of ACTH testing is estimated to be
approximately GBP10-15 million.
For further information:
Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 0660
Patricio Lacalle, Chief Executive Officer
Paul Martin, Group Finance Director
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel
Oliver Jackson
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEASAAEFAXEFF
(END) Dow Jones Newswires
February 02, 2017 10:14 ET (15:14 GMT)
Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart
From Apr 2024 to May 2024
Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart
From May 2023 to May 2024